IL10 and systemic lupus erythematosus: In an early clinical study, weekly subcutaneous administration of different doses of hCDR1 (Edratide)-−0.5, 1.0, and 2.5 mg—was found to be effective in ameliorating the manifestations and in downregulating the production of proinflammatory and proapoptotic cytokines in SLE patients; the affected proapoptotic proteins include IL-1β, TNF-α, IFN-γ, IL-10, caspase 3, and caspase 8 (145).